lobbying_activities: 2771817
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2771817 | 4dd1cff4-6dff-480d-b120-0beed0556848 | Q1 | AMERICAN PHARMACISTS ASSOCIATION | 3071 | AMERICAN PHARMACISTS ASSOCIATION | 2022 | first_quarter | CSP | S. 1388 -- Prescription Pricing for the People Act of 2021, a bill to require the Federal Trade Commission (FTC) to report about anticompetitive practices and other trends within the pharmaceutical supply chain that may impact the cost of prescriptions drugs. The FTC also must provide recommendations to increase transparency in the supply chain and prevent anticompetitive practices. S. 298/H.R. 1829 -- Pharmacy Benefit Manager Accountability Study Act of 2021, a bill to require the Government Accountability Office to report on the role of pharmacy benefit managers in the pharmaceutical supply chain and recommend legislative actions to lower the cost of prescription drugs. The report must address the use of rebates and fees, the average prior authorization approval time, and the use of step therapy within the 10 largest pharmacy benefit managers. | HOUSE OF REPRESENTATIVES,SENATE | 35000 | 0 | 0 | 2022-04-12T09:34:20-04:00 |